LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
771
via seekingalpha.comMarkets

Celldex falls about 2% as phase 2 barzolvolimab trial misses atopic dermatitis endpoints

FROM THE WIRE · SEEKINGALPHA.COM

Celldex shares fall about 2% after its phase 2 barzolvolimab trial misses atopic dermatitis endpoints. Read more here.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA phase 2 trial miss is relevant for the stock and expectations for the drug.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Celldex shares fall about 2%.
  2. 02The phase 2 barzolvolimab trial misses atopic dermatitis endpoints.
  3. 03The company abandons the atopic dermatitis program.

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.